On the contrary, the cabozantinib treatment schedule (alone or in sequence) of the 786-O cell line may affect the AKT signaling process, which is one of the most important pathways involved in cell proliferation, survival and transformation occurring in RCC tumorigenesis [10,76], as well as acquired resistance [77]. This evidence concerns the gene AKT1 and renal cell carcinoma.